Sign In
Buy IMGN
$31.23
+0 (+0%)
At Close: May 08, 2024
Good News for Patients Is Lifting These 2 Biopharma Stocks
08:46am, Wednesday, 03'rd May 2023
Markets were waiting to see what the Federal Reserve will do with interest rates later today. Eli Lilly announced favorable trial results for its Alzheimer's treatment.
ImmunoGen (IMGN) Q1 Earnings Beat, Elahere Uptake Encouraging
12:10pm, Monday, 01'st May 2023
ImmunoGen (IMGN) reports impressive Q1 earnings results on strong adoption of sole-marketed drug Elahere. The company raises financial guidance for 2023.
ImmunoGen shares pop on 1Q sales of ovarian cancer drug
01:57pm, Friday, 28'th Apr 2023
ImmunoGen Inc shares rocketed higher Friday after the company's first quarter sales impressed investors. The Massachusetts-based company posted revenue of $49.9 million, including $29.5 million of n
Why Shares of ImmunoGen Jumped Friday
12:03pm, Friday, 28'th Apr 2023
ImmunoGen's ovarian cancer therapy, Elahere, has had a strong launch. The company increased its revenue guidance for 2023.
ImmunoGen (IMGN) Reports Q1 Loss, Tops Revenue Estimates
09:09am, Friday, 28'th Apr 2023
ImmunoGen (IMGN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.10 per share a year ago.
5 Hot Penny Stocks To Watch Before Next Week
03:09pm, Thursday, 27'th Apr 2023
5 penny stocks to watch. The post 5 Hot Penny Stocks To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2023 Operating Results
04:01pm, Thursday, 13'th Apr 2023
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will ho
Could This Move Make Vertex's Next Blockbuster Even Bigger?
05:30am, Wednesday, 12'th Apr 2023
Vertex Pharmaceuticals recently completed regulatory requests for its blood disorder candidate, exa-cel. Exa-cel has what it takes to become a blockbuster over time.
ImmunoGen, Inc. (IMGN) Q4 2022 Earnings Call Transcript
10:33am, Wednesday, 01'st Mar 2023
ImmunoGen, Inc. (NASDAQ:IMGN ) Q4 2022 Earnings Conference Call March 1, 2023 8:00 AM ET Company Participants Anabel Chan - Head, IR Mark Enyedy - President and CEO Anna Berkenblit - Chief Medical Off
ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates
09:02am, Wednesday, 01'st Mar 2023
ImmunoGen (IMGN) delivered earnings and revenue surprises of 20.69% and 132.98%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for
03:00pm, Wednesday, 22'nd Feb 2023 Zacks Investment Research
ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Misses Revenue Estimates
01:15pm, Wednesday, 22'nd Feb 2023 Zacks Investment Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 65.09% and 3.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock
ImmunoGen: Despite First Approval, They Have Many Problems
09:48am, Tuesday, 14'th Feb 2023
IMGN received its first approval after 40 long years. However, ocular toxicity and confusing PFS are some of the problems here.
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
04:30pm, Wednesday, 01'st Feb 2023
WALTHAM, Mass.--( BUSINESS WIRE )--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following pr
Cigna (CI) to Post Q4 Earnings: Here's What You Should Know
05:55pm, Tuesday, 31'st Jan 2023 Zacks Investment Research
Cigna's (CI) fourth-quarter results are likely to reflect increased Evernorth and Cigna Healthcare profits.
